Background-Pituitary adenylate cyclase activating peptides (PACAPs) are potent endothelium independent dilators of human coronary arteries; however, their eVects on human pulmonary arteries are unknown. Methods-The vasorelaxant eVects of PACAP27 on human pulmonary segmental arteries were studied and the specific potassium (K + ) channel regulatory mechanisms in the vasorelaxant eVects were tested by means of isometric contraction experiments. Results-PACAP27 produced dose dependent relaxations of 10 µM rings preconstricted with prostaglandin F 2 (PGF 2 ) with half maximal relaxation (IC 50 ) at 17 nM. Pretreatment of the vessels with the ATP sensitive K + (K ATP ) channel blocker glibenclamide (1 µM) or with the Ca 2+ activated K + (K Ca ) channel blocker iberiotoxin (100 nM) inhibited the PACAP27 induced relaxation. Conclusions-These results provide evidence that PACAPs are potent vasodilators of human pulmonary arteries and that this relaxation might be mediated by opening of K ATP and K Ca channels. (Thorax 1998;53:586-587) 
Pituitary adenylate cyclase activating polypeptides (PACAP38 and PACAP27) induce specific eVects on the cardiovascular system in rats, 1 cats, 2 and sheep. 3 Our previous studies have shown that PACAP27 and PACAP38 are potent endothelium independent dilators of isolated human and porcine epicardial coronary arteries. 4 5 Since the vasorelaxant eVects of PACAP27 are inhibited by K + channel blockers, we have suggested that specific K + channel regulatory mechanisms may be involved in the relaxation of human coronary arteries. 5 Since PACAP has recently been shown to stimulate L-type Ca 2+ channels in smooth muscle cells of the rat tail artery, 6 it might be expected that PACAP can also exhibit vasoconstrictory eVects. However, no information has been reported on the eVects of PACAP on human pulmonary arteries. Furthermore, the contractile behaviour of pulmonary arteries diVers from other arterial vessels, and K + channels are diverse and their distribution varies in diVerent vascular beds and species.
A study was undertaken to test whether human segmental pulmonary arteries are dilated by PACAP27. Glibenclamide and iberiotoxin were used at concentrations that selectively block ATP sensitive (K ATP ) and large conductance calcium activated K + channels (K Ca ), respectively, in arterial smooth muscle 7 to investigate the functional importance of the linkage between K ATP and K Ca channel activation and pulmonary relaxation induced by PACAP27.
Methods
Human pulmonary segmental arteries (diameter 1-3 mm) were obtained from tumour free lung parts of patients who had undergone lobectomy or pulmonectomy due to peripheral lung cancer. The isometric tension of isolated vessel rings (4 mm in length) was measured isometrically as previously described. 5 The pulmonary arteries were stretched stepwise to a resting tension of about 5 mN and allowed to equilibrate for at least two hours. The cumulative concentration-response curves with PACAP27 were measured after precontraction of the rings with prostaglandin F 2 (PGF 2 ) (10 µM). Non-linear regression analysis was used to calculate half maximal relaxation (IC 50 ) values and Hill coeYcients.
STATISTICAL ANALYSIS
All values are given as mean (SE). The term n represents the number of vessel rings, only one vessel ring per patient was used for each concentration-response curve. ANOVA on ranks and the Wilcoxon rank sum test were used to determine significant diVerences between the diVerent concentration-response curves at each point. A value of p<0.05 was considered statistically significant.
Results

PULMONARY RELAXATION BY PACAP27
In human pulmonary arteries PACAP27 induced dose dependent relaxations of rings preconstricted with 10 µM PGF 2 , with IC 50 values at 17 nM (fig 1) . The Hill coeYcient was 0.63. PACAP27 induced relaxation to approximately 35% of preconstricted values at 0.1 µM. The eVects of PACAP were completely reversible after washout (data not shown).
EFFECTS OF GLIBENCLAMIDE AND IBERIOTOXIN ON RELAXATION INDUCED BY PACAP27
To elucidate the role of K + channels in the vasorelaxant mechanism of the PACAPs, we tested the eVects of the ATP sensitive K + channel (K ATP ) blocker glibenclamide and of the calcium activated K + channel (K Ca ) blocker iberiotoxin on the PACAP27 induced relaxation of human pulmonary arteries. The concentration-response curves for relaxation induced by PACAP27 after pretreatment of PGF 2 precontracted pulmonary rings with glibenclamide (1 µM), iberiotoxin (100 nM), or both in combination are also shown in fig 1. Both glibenclamide and iberiotoxin significantly attenuated the PACAP27 induced relaxation, but the eVect of iberiotoxin was more pronounced. Application of a combination of glibenclamide (1 µM) and iberiotoxin (100 nM) did not result in an additive eVect.
Discussion
These results provide the first evidence that PACAP27 is a potent dilator of human segmental pulmonary arteries. We have shown that glibenclamide (a specific K ATP channel blocker 7 ) and iberiotoxin (a selective K Ca channel blocker 7 ) inhibit PACAP27 induced relaxation of human pulmonary arteries. Similar eVects were observed in human coronary arteries. 5 Furthermore, PACAP27 stimulated K ATP and K Ca currents in freshly isolated human coronary artery smooth muscle cells. 5 We therefore propose the following cascade of events leading to relaxation of both human pulmonary and coronary arteries by PACAPs: (1) activation of K ATP and K Ca channels in smooth muscle cells, (2) increase in K + eZux, (3) membrane hyperpolarisation, (4) closure of voltage dependent Ca 2+ channels, and (5) decrease of Ca 2+ entry and vasorelaxation. The mechanism by which PACAPs can stimulate K ATP and K Ca channels in smooth muscle is unknown, but might involve activation of adenylyl cyclase which has been shown in rat aortic smooth muscle cell homogenates. 8 It has also been reported that activation of adenylyl cyclase and an increase in cAMP can stimulate K ATP and K Ca channels in smooth muscle cells. 7 It therefore seems likely that this pathway is also involved in the stimulation of these channels in human pulmonary arteries, but data concerning the coupling between increased cAMP and activation of K ATP and K Ca channels (including K Ca currents activated by Ca sparks) in human vascular smooth muscle cells are still lacking. However, it is also possible that the eVects of PACAP are mediated by G proteins. These have been reported to stimulate potassium channels directly, in particular K Ca , in vascular smooth muscle cells. 9 PACAPs exert potent vasodilation in vivo in diVerent perfusion beds, including lung. 10 In the lung PACAP positive nerve fibres were immunohistochemically demonstrated around small blood vessels. These nerve fibres also store vasoactive intestinal polypeptide (VIP), as revealed by double immunostaining.
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Besides VIP, PACAP is thus a novel neurotransmitter for non-adrenergic/non-cholinergic innervation of lung blood vessels.
The results of the present study suggest that PACAPs may have a physiological significance in the pulmonary circulation since they are potent dilators of human pulmonary arteries with an IC 50 in the low nanomolar range, and they stimulate K ATP and K Ca channels in smooth muscle cells to exert their vasodilatory action. 
